UNSPSC 51272604: Anileridine phosphate

This classification denotes an opioid receptor agonist with the molecular formula C22H28N2O2.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3584484N8V. European Medicines Agency schedules anileridine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00533MIG. The term anileridine phosphate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule anileridine phosphate under HS 29333990 and SITC 51574.

As of Q4 2014, ANILERIDINE PHOSPHATE remains US FDA's Preferred Term for this commodity. Anileridine phosphate bears US NLM identifiers UMLS ID C0770428 and NCI Concept Code C87352. SMILES: CCOC(=O)C1(CCN(CC1)CCC2CCC(CC2)N)C3CCCCC3.OP(=O)(O)O.

UNSPSC 51272604 Anileridine phosphate is a Commodity code that in practice covers a narrow slice of pharmaceutical procurement activity in state and local government — specifically the supply of controlled and non-controlled pharmaceutical products, including opioid analgesics and their antagonists, to public health agencies and multistate cooperative purchasing groups. Recent opportunities show state and local buyers sourcing naloxone (an opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products through cooperative vehicles, and direct-to-manufacturer prescription fulfillment models. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and other participating jurisdictions). Work under the code ranges from direct procurement of naloxone kits for community health initiatives to large-scale cooperative contracts for generic pharmaceutical and OTC supply chains serving multiple state and local facilities.

Activity concentrates in Florida, Texas, and Minnesota, with secondary participation from Oregon through the MMCAP cooperative. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the county community health building; the Texas HHS Commission's RFI No. HHS0017013 (posted April 3, 2026) gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and the Minnesota Department of Administration's MMCAP RFP (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with awards effective July 1, 2026. The MMCAP procurement weights price competitiveness at 75 percent and requires vendors to maintain relationships with at least two of three authorized wholesalers, comply with cGMP and Drug Supply Chain Security Act standards, and carry commercial general liability insurance of $5 million per occurrence.